Investigational Drug for Heart Failure has Little Impact on

Heart failure patients taking the investigational drug omecamtiv mecarbil, which has been previously shown to improve long-term outcomes, see little impact on t

Related Keywords

Massachusetts , United States , Alain Cohen Solal , Fady Malik , Stuart Kupfer , Lisa Meng , John Teerlink , David Whellan , Marco Metra , Justin Ezekowitz , Michael Felker , Gregory Lewis , Stephen Heitner , Adriaan Voors , Piotr Ponikowski , Kieran Docherty , American College Of Cardiology Scientific Sessions , Duke Clinical Research Institute , Duke Clinical Research , Cardiology Scientific , Heart Failure , Multicenter Exercise Tolerance Evaluation , Omecamtiv Mecarbil Related , Increased Contractility , Global Approach , Massachusetts General Hospital , Newswise , Eart Failure Exercise Tolerance Heart Disease , Cardiovascular Health , Heart Disease , Pharmaceuticals , Mbargoed Feed Hidden , All Journal News , Duke Health ,